Lynk Pharmaceuticals Announces Completion of Patient Enrollment in Phase III Clinical Trial of Zemprocitinib for Ankylosing Spondylitis

Phase 3ZemprocitinibPositive

AI Analysis

Summary

Lynk Pharmaceuticals announced completion of patient enrollment in a Phase III clinical trial of Zemprocitinib for ankylosing spondylitis on July 9, 2026. The trial enrollment milestone represents progress toward potential regulatory submission.

Clinical Trial Data

Phase

Phase III

Outcome Details

Patient enrollment completed

Importance:6/10

Sentiment:

0.30

Phase 3Enrollment CompleteAnkylosing SpondylitisImmunologyInflammatory Disease

Related Companies

$HGZDY $CHHE

Read the original article

Published by PR Newswire Clinical Trials on July 15, 2026 12:00 AM

Read Original